RBC Europe’s NanoViricides NNVC Stock Holding History

RBC Europe’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8	Closed	-$37	–	956
2021 Q3	$37	Hold	8	–	–	﹤0.01%	1227
2021 Q2	$37	Hold	8	–	–	﹤0.01%	1219
2021 Q1	$38	Hold	8	–	–	﹤0.01%	1169
2020 Q4	$23	Hold	8	–	–	﹤0.01%	1143
2020 Q3	$31	Hold	8	–	–	﹤0.01%	1089
2020 Q2	$60	Hold	8	–	–	﹤0.01%	1048
2020 Q1	$46	Hold	8	–	–	﹤0.01%	1029
2019 Q4	$20	Buy	8 +1	+14%	+$2	﹤0.01%	1046
2019 Q3	$14	Hold	7	–	–	﹤0.01%	1048
2019 Q2	$34	Hold	7	–	–	﹤0.01%	1057
2019 Q1	$39	Hold	7	–	–	﹤0.01%	1070
2018 Q4	$29	Hold	7	–	–	﹤0.01%	1083
2018 Q3	$51	Hold	7	–	–	﹤0.01%	1121
2018 Q2	$63	Hold	7	–	–	﹤0.01%	1131
2018 Q1	$118	Hold	7	–	–	﹤0.01%	1102
2017 Q4	$126	Hold	7	–	–	﹤0.01%	1116
2017 Q3	$163	Buy	+7	New	+$188	﹤0.01%	1113

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

RBC Europe's NNVC Position: Q4 2021 in Review

RBC Europe sold out of NanoViricides (NNVC) in Q4 2021, closing a stake of 8 shares — an estimated $37 sold.

RBC Europe first reported a position in NNVC in Q3 2017 and held it in 17 quarters. The position peaked at $163 in Q3 2017. 29 funds tracked by Wall St. Rank hold NNVC as of Q4 2021.

RBC Europe reported no remaining NanoViricides position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 8 NanoViricides shares in Q4 2021, an estimated $37.
RBC Europe first reported a position in NanoViricides in Q3 2017 and held it in 17 quarters.
RBC Europe's NanoViricides position peaked at $163 in Q3 2017.
29 funds tracked by Wall St. Rank held NanoViricides as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.